^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SRPRB overexpression

    i
    Other names: SRPRB, SRP Receptor Subunit Beta, SR-Beta, APMCF1, Signal Recognition Particle Receptor Subunit Beta, Signal Recognition Particle Receptor, B Subunit, Signal Recognition Particle Receptor, Beta Subunit, SRP Receptor Beta Subunit, Protein APMCF1
    Entrez ID:
    58477
    2years
    Selenomethionine Suppress the Progression of Poorly Differentiated Thyroid Cancer via LncRNA NONMMUT014201/miR-6963-5p/Srprb Pathway. (PubMed, Comb Chem High Throughput Screen)
    Collectively, SeMet inhibits the growth of PDTC in a dose-dependent manner through LncRNA NONMMUT014201/miR-6963-5p/Srprb signal pathway, thus suggesting that SeMet might be a potential drug for PDTC treatment.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MMP2 (Matrix metallopeptidase 2) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen) • SRPRB (SRP Receptor Subunit Beta)
    |
    BCL2 expression • SRPRB overexpression • PCNA expression
    |
    selenomethionine (SLM)